

Meningococcal Vaccines

Vaccine Description	<ul style="list-style-type: none"> • Brands: Menomune® and Menactra® • Inactivated, bacterial polysaccharide (Menomune®) • Inactivated, bacterial polysaccharide conjugate (Menactra®) • Contains thimerosal (only multidose Menomune®) and latex (stopper only for Menactra®) • See package insert 	
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: SC (Menomune®) and IM (Menactra®) (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) • See package insert 	
Indications	<ul style="list-style-type: none"> • All children at age 11 to 12 years and unvaccinated adolescents at subsequent visit • College freshmen living in dormitories • Children older than 2 years who: <ul style="list-style-type: none"> - have functional or anatomic asplenia - are traveling to or living in an endemic area - have certain immune system disorders - have been exposed to meningitis during an outbreak • Menactra® is preferred, but is only licensed for use in people between the ages of 2 to 55 years • Menomune® may be given to children 3 months to 2 years if provider determines it is necessary 	
Administration Schedule	Age	Dose
	3 months to 2 years of age	2 doses of the age-appropriate vaccine, 3 months apart if indicated by the provider
	2 years or older	1 dose of the age-appropriate vaccine
Booster	<ul style="list-style-type: none"> • Menomune®: 3-5 years • Menactra®: <ul style="list-style-type: none"> • 5 years if 1st dose given at 7 years of age or older • 3 years if 1st dose given at 2 through 6 years of age 	

Continued on Next Page